1 1. Factors associated with virological response to etravirine in non nucleoside reverse transcriptase inhibitor experienced HIV-1 infected patients. Marcelin AG, Flandre P, Descamps D, Morand-Joubert L, Charpentier C, Izopet J, Trabaud MA, Saoudin H, Delaugerre C, Tamalet C, Cottalorda J, Bouvier-Alias M, Bettinger D, Dos Santos G, Ruffault A, Alloui C, Henquell C, Rogez S, Barin F, Signori-Schmuck A, Vallet S, Masquelier B, Calvez V; the ANRS AC11 Resistance study group. Antimicrob Agents Chemother Nov High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial. Yazdanpanah Y, Fagard C, Descamps D, Taburet AM, Colin C, Roquebert B, Katlama C, Pialoux G, Jacomet C, Piketty C, Bollens D, Molina JM, Chêne G; ANRS 139 TRIO Trial Group. Clin Infect Dis Nov 1;49(9): Factors influencing peripheral blood mononuclear cell-associated HIV-1 DNA level after longterm suppressive antiretroviral therapy in 236 patients. Burgard M, Boufassa F, Viard JP, Garrigue I, Ruffault A, Izopet J, Vabret A, Descamps D, Colson P, Seigneurin JM, Rouzioux C; ANRS AC11 Working Group. AIDS Oct 23;23(16): Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study. Landman R, Capitant C, Descamps D, Chazallon C, Peytavin G, Katlama C, Pialoux G, Bentata M, Brun-Vézinet F, Aboulker JP, Yéni P; ANRS 127 Study Group. J Antimicrob Chemother Jul;64(1): Good response to lopinavir/ritonavir-containing antiretroviral regimens in antiretroviral-naive HIV-2-infected patients. Bénard A, Damond F, Campa P, Peytavin G, Descamps D, Lascoux-Combes C, Taieb A, Simon F, Autran B, Brun-Vézinet F, Chêne G, Matheron S; ANRS CO5 HIV-2 Cohort Study Group. AIDS Jun 1;23(9): Gag mutations strongly contribute to HIV-1 resistance to protease inhibitors in highly drugexperienced patients besides compensating for fitness loss. Dam E, Quercia R, Glass B, Descamps D, Launay O, Duval X, Kräusslich HG, Hance AJ, Clavel F; ANRS 109 Study Group. PLoS Pathog Mar;5(3):e The human immunodeficiency virus type 2 Vpx protein usurps the CUL4A-DDB1 DCAF1 ubiquitin ligase to overcome a postentry block in macrophage infection. Bergamaschi A, Ayinde D, David A, Le Rouzic E, Morel M, Collin G, Descamps D, Damond F, Brun- Vezinet F, Nisole S, Margottin-Goguet F, Pancino G, Transy C. J Virol May;83(10): Mutations associated with virological response to darunavir/ritonavir in HIV-1-infected protease inhibitor-experienced patients. Descamps D, Lambert-Niclot S, Marcelin AG, Peytavin G, Roquebert B, Katlama C, Yeni P, Felices M, Calvez V, Brun-Vézinet F. J Antimicrob Chemother Mar;63(3): A new human immunodeficiency virus derived from gorillas. Plantier JC, Leoz M, Dickerson JE, De Oliveira F, Cordonnier F, Lemée V, Damond F, Robertson DL, Simon F.
2 Nat Med Aug;15(8): Immunovirological and therapeutic follow-up of HIV-1/HIV-2-dually seropositive patients. Landman R, Damond F, Gerbe J, Brun-Vezinet F, Yeni P, Matheron S. AIDS Jan 28;23(3): Development of a didanosine genotypic resistance interpretation system based on large derivation and validation datasets. Assoumou L, Cozzi-Lepri A, Brun-Vézinet F, Degruttola V, Kuritzkes DR, Phillips A, Zolopa A, Miller V, Flandre P, Costagliola D; on behalf of the Standardization, Clinical Relevance of HIV Drug Resistance Testing Project from the Forum for Collaborative HIV Research. AIDS Oct Benefit of therapeutic drug monitoring of protease inhibitors in HIV-infected patients depends on PI used in HAART regimen--anrs 111 trial. Duval X, Mentré F, Rey E, Auleley S, Peytavin G, Biour M, Métro A, Goujard C, Taburet AM, Lascoux C, Panhard X, Tréluyer JM, Salmon-Céron D; Cophar 2 Study Group. Fundam Clin Pharmacol Aug;23(4): Factors associated with non-adherence to long-term highly active antiretroviral therapy: a 10 year follow-up analysis with correction for the bias induced by missing data. Protopopescu C, Raffi F, Roux P, Reynes J, Dellamonica P, Spire B, Leport C, Carrieri MP; ANRS CO8 APROCO-COPILOTE Study Group. J Antimicrob Chemother Sep;64(3): Predictive value of HIV-1 genotypic resistance test interpretation algorithms. Rhee SY, Fessel WJ, Liu TF, Marlowe NM, Rowland CM, Rode RA, Vandamme AM, Van Laethem K, Brun-Vezinet F, Calvez V, Taylor J, Hurley L, Horberg M, Shafer RW. J Infect Dis Aug 1;200(3): Uncontrolled viral replication as a risk factor for non-aids severe clinical events in HIVinfected patients on long-term antiretroviral therapy: APROCO/COPILOTE (ANRS CO8) cohort study. Ferry T, Raffi F, Collin-Filleul F, Dupon M, Dellamonica P, Waldner A, Strady C, Chêne G, Leport C, Moing VL; ANRS CO8 (APROCO-COPILOTE) Study Group. J Acquir Immune Defic Syndr Aug 1;51(4): Influence of pharmacogenetics on indinavir disposition and short-term response in HIV patients initiating HAART. Bertrand J, Treluyer JM, Panhard X, Tran A, Auleley S, Rey E, Salmon-Céron D, Duval X, Mentré F; COPHAR2-ANRS 111 Study Group. Eur J Clin Pharmacol Jul;65(7): Ten-year incidence and risk factors of bone fractures in a cohort of treated HIV1-infected adults. Collin F, Duval X, Le Moing V, Piroth L, Al Kaied F, Massip P, Villes V, Chêne G, Raffi F; ANRS CO8 APROCO-COPILOTE study group. AIDS May 15;23(8): Costs and cost-effectiveness of different follow-up schedules for detection of occupational hepatitis C virus infection. Deuffic-Burban S, Abiteboul D, Lot F, Branger M, Bouvet E, Yazdanpanah Y. Gut Jan;58(1): Efficacy and safety of darunavir/ritonavir in treatment-experienced HIV type-1 patients in the POWER 1, 2 and 3 trials at week 96.
3 Arastéh K, Yeni P, Pozniak A, Grinsztejn B, Jayaweera D, Roberts A, Hoy J, De Meyer S, Vangeneugden T, Tomaka F. Antivir Ther. 2009;14(6): , Cerebral microbleeds are frequent in infective endocarditis: a case-control study. Klein I, Iung B, Labreuche J, Hess A, Wolff M, Messika-Zeitoun D, Lavallée P, Laissy JP, Leport C, Duval X; IMAGE Study Group. Stroke Nov;40(11): Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials. Katlama C, Haubrich R, Lalezari J, Lazzarin A, Madruga JV, Molina JM, Schechter M, Peeters M, Picchio G, Vingerhoets J, Woodfall B, De Smedt G; DUET-1, DUET-2 study groups. AIDS Nov 13;23(17): Short-term randomized proof-of-principle trial of TMC278 in patients with HIV type-1 who have previously failed antiretroviral therapy. Arastéh K, Rieger A, Yeni P, Pozniak A, Boogaerts G, van Heeswijk R, de Béthune MP, Peeters M, Woodfall B. Antivir Ther. 2009;14(5): Activation and coagulation biomarkers are independent predictors of the development of opportunistic disease in patients with HIV infection. Rodger AJ, Fox Z, Lundgren JD, Kuller LH, Boesecke C, Gey D, Skoutelis A, Goetz MB, Phillips AN; INSIGHT Strategies for Management of Antiretroviral Therapy (SMART) Study Group. J Infect Dis Sep 15;200(6): Impact of HIV infection on severity of imported malaria is restricted to patients with CD4 cell counts < 350 cells/microl. Mouala C, Guiguet M, Houzé S, Damond F, Pialoux G, Viget N, Costagliola D, Le Bras J, Matheron S; FHDH-ANRS CO4 Clinical Epidemiology Group. AIDS Sep 24;23(15): Systematic evaluation and description of anal pathology in HIV-infected patients during the HAART era. Abramowitz L, Benabderrahmane D, Baron G, Walker F, Yeni P, Duval X. Dis Colon Rectum Jun;52(6): Stable frequency of HIV-1 transmitted drug resistance in patients at the time of primary infection over in France. Chaix ML, Descamps D, Wirden M, Bocket L, Delaugerre C, Tamalet C, Schneider V, Izopet J, Masquelier B, Rouzioux C, Meyer L, Costagliola D; ANRS AC11 Resistance Group; Cohort PRIMO ANRS CO 6; FHDH ANRS CO4 Study Groups. AIDS Mar 27;23(6): Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy: not all AIDS-defining conditions are created equal.
4 Antiretroviral Therapy Cohort Collaboration (ART-CC), Mocroft A, Sterne JA, Egger M, May M, Grabar S, Furrer H, Sabin C, Fatkenheuer G, Justice A, Reiss P, d'arminio Monforte A, Gill J, Hogg R, Bonnet F, Kitahata M, Staszewski S, Casabona J, Harris R, Saag M. Clin Infect Dis Apr 15;48(8): Changes in cancer mortality among HIV-infected patients: the Mortalité 2005 Survey. Bonnet F, Burty C, Lewden C, Costagliola D, May T, Bouteloup V, Rosenthal E, Jougla E, Cacoub P, Salmon D, Chêne G, Morlat P; Agence Nationale de Recherches sur le Sida et les Hépatites Virales EN19 Mortalité Study Group; Mortavic Study Group. Clin Infect Dis Mar 1;48(5): Antiviral activity and safety of aplaviroc, a CCR5 antagonist, in combination with lopinavir/ritonavir in HIV-infected, therapy-naïve patients: results of the EPIC study (CCR100136). Yeni P, Lamarca A, Berger D, Cimoch P, Lazzarin A, Salvato P, Smaill FM, Teofilo E, Madison SJ, Nichols WG, Adkison KK, Bonny T, Millard J, McCarty D; EPIC (CCR100136) study team. HIV Med Feb;10(2): How does loss to follow-up influence cohort findings on HIV infection? A joint analysis of the French hospital database on HIV, Mortalité 2000 survey and death certificates. Lanoy E, Lewden C, Lièvre L, Tattevin P, Boileau J, Aouba A, Chêne G, Costagliola D; Clinical Epidemiologic Group of the French Hospital Database on HIV (ANRS CO4 FHDH); Groupe d'etude Mortalité HIV Med Apr;10(4): Interleukine-2 therapy does not increase the risk of Hodgkin or non-hodgkin lymphoma in HIV-infected patients: results from FHDH ANRS CO4. Fontas E, Kousignian I, Pradier C, Duvivier C, Poizot-Martin I, Durier C, Jarrousse B, Weiss L, Levy Y, Costagliola D; FHDH ANRS CO4 ANRS CO141. J Acquir Immune Defic Syndr Feb 1;50(2): Interruption of antiretroviral therapy is associated with increased plasma cystatin C. Mocroft A, Wyatt C, Szczech L, Neuhaus J, El-Sadr W, Tracy R, Kuller L, Shlipak M, Angus B, Klinker H, Ross M; INSIGHT SMART Study Group. AIDS Jan 2;23(1): Rosuvastatin versus pravastatin in dyslipidemic HIV-1-infected patients receiving protease inhibitors: a randomized trial. Aslangul E, Assoumou L, Bittar R, Valantin MA, Kalmykova O, Peytavin G, Fiévet MH, Boccara F, Bonnefont-Rousselot D, Melchior JC, Giral P, Costagliola D. AIDS Oct Contribution and limit of the model of perfused cotyledon to the study of placental transfer of drugs. Example of a protease inhibitor of HIV: nelfinavir.
5 Gavard L, Beghin D, Forestier F, Cayre Y, Peytavin G, Mandelbrot L, Farinotti R, Gil S. Eur J Obstet Gynecol Reprod Biol Dec;147(2): Clinical and resistance consequences of misquantification of plasma and cerebrospinal fluid human immunodeficiency virus type 1 (HIV-1) RNA in samples from an HIV-1 subtype G-infected patient. Delaugerre C, Denis B, Peytavin G, Palmer P, Mourez T, Le Goff J, Molina JM, Simon F. J Clin Microbiol Nov;47(11): Benefit of therapeutic drug monitoring of protease inhibitors in HIV-infected patients depends on PI used in HAART regimen--anrs 111 trial. Duval X, Mentré F, Rey E, Auleley S, Peytavin G, Biour M, Métro A, Goujard C, Taburet AM, Lascoux C, Panhard X, Tréluyer JM, Salmon-Céron D; Cophar 2 Study Group. Fundam Clin Pharmacol Aug;23(4): Absence of a relation between efavirenz plasma concentrations and toxicity-driven efavirenz discontinuations in the EuroSIDA study. van Luin M, Bannister WP, Mocroft A, Reiss P, Di Perri G, Peytavin G, Molto J, Karlson A, Castagna A, Beniowski M, Lundgren JD, Burger DM; EuroSIDA Study Group. Antivir Ther. 2009;14(1):75-83 Peytavin G. 39 Clinical pharmacokinetic of maraviroc] Med Mal Infect Mar;38 Suppl 1:S High rate of early virological failure with the once-daily tenofovir/lamivudine/nevirapine combination in naive HIV-1-infected patients. Rey D, Hoen B, Chavanet P, Schmitt MP, Hoizey G, Meyer P, Peytavin G, Spire B, Allavena C, Diemer M, May T, Schmit JL, Duong M, Calvez V, Lang JM. J Antimicrob Chemother Feb;63(2): Population pharmacokinetics of tenofovir in HIV-1-infected pregnant women and their neonates (ANRS 12109). Hirt D, Urien S, Ekouévi DK, Rey E, Arrivé E, Blanche S, Amani-Bosse C, Nerrienet E, Gray G, Kone M, Leang SK, McIntyre J, Dabis F, Tréluyer JM; ANRS Clin Pharmacol Ther Feb;85(2): Perinatal acquisition of drug-resistant HIV-1 infection: mechanisms and long-term outcome. Delaugerre C, Chaix ML, Blanche S, Warszawski J, Cornet D, Dollfus C, Schneider V, Burgard M, Faye A, Mandelbrot L, Tubiana R, Rouzioux C; ANRS French Perinatal Cohort. Retrovirology Sep 19;6:85.
6 43 No relation between in-utero exposure to HAART and intrauterine growth retardation. Briand N, Mandelbrot L, Le Chenadec J, Tubiana R, Teglas JP, Faye A, Dollfus C, Rouzioux C, Blanche S, Warszawski J; ANRS French Perinatal Cohort. AIDS Jun 19;23(10): Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy: not all AIDS-defining conditions are created equal. Antiretroviral Therapy Cohort Collaboration (ART-CC), Mocroft A, Sterne JA, Egger M, May M, Grabar S, Furrer H, Sabin C, Fatkenheuer G, Justice A, Reiss P, d'arminio Monforte A, Gill J, Hogg R, Bonnet F, Kitahata M, Staszewski S, Casabona J, Harris R, Saag M. Clin Infect Dis Apr 15;48(8): Interleukine-2 therapy does not increase the risk of Hodgkin or non-hodgkin lymphoma in HIV-infected patients: results from FHDH ANRS CO4. Fontas E, Kousignian I, Pradier C, Duvivier C, Poizot-Martin I, Durier C, Jarrousse B, Weiss L, Levy Y, Costagliola D; FHDH ANRS CO4 ANRS CO141. J Acquir Immune Defic Syndr Feb 1;50(2): Amniocentesis and mother-to-child human immunodeficiency virus transmission in the Agence Nationale de Recherches sur le SIDA et les Hépatites Virales French Perinatal Cohort. Mandelbrot L, Jasseron C, Ekoukou D, Batallan A, Bongain A, Pannier E, Blanche S, Tubiana R, Rouzioux C, Warszawski J; ANRS French Perinatal Cohort (EPF). Am J Obstet Gynecol Feb;200(2):160.e Tenofovir-Emtricitabine-Efavirenz in HIV-1-Infected Adults in Senegal: A 96-Week Pilot Trial in Treatment-Naive Patients. Landman R, Poupard M, Diallo M, Gueye NF, Diakhate N, Ndiaye B, Kane CT, Trylesinski A, Diop H, Mboup S, Fall MB, Deleporte E, Benalycherif AD, Girard PM, Sow PS. J Int Assoc Physicians AIDS Care (Chic Ill) Sep Simplification and first validation of a short battery of patient questionnaires for clinical management of HIV-infected patients: The HIV-SQUAD (Symptom Quality of life Adherence) Questionnaire. Spire B, Arnould B, Barbier F, Durant J, Gilquin J, Landman R, Carret S, Saussier C, El Kebir S, Cohen-Codar I. HIV Clin Trials Jul-Aug;10(4): Activation and coagulation biomarkers are independent predictors of the development of opportunistic disease in patients with HIV infection. Rodger AJ, Fox Z, Lundgren JD, Kuller LH, Boesecke C, Gey D, Skoutelis A, Goetz MB, Phillips AN; INSIGHT Strategies for Management of Antiretroviral Therapy (SMART) Study Group.
7 J Infect Dis Sep 15;200(6): HIV genetic diversity and its consequences.] Roquebert B, Damond F, Brun-Vézinet F, Descamps D. Pathol Biol (Paris) Mar;57(2):142-8.
1 Appendix B: DESCRIPTION OF HIV PROGRESSION SIMULATION * Our simulation separately tracks the number of accumulated genetic mutations that may confer resistance to each of the three main drug categories
HIV Drug resistanceimplications for therapy Deenan Pillay Africa Centre for Health and Population Studies, UKZN University College London Potential implications of HAART without virological monitoring:
Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents Visit the AIDSinfo website to access the most up-to-date guideline. Register for e-mail notification of guideline
Antiretroviral therapy for HIV infection in infants and children: Towards universal access Executive summary of recommendations Preliminary version for program planning 2010 Executive summary Tremendous
Clinical Commissioning Policy: Dolutegravir for treatment of HIV- 1 in adults and adolescents Reference: NHS England B06/P/a 1 NHS England Clinical Commissioning Policy: Dolutegravir for treatment of HIV-1
Positive impact of HCV treatment initiation on health outcomes in injecting drug users Perrine ROUX, PhD Substance Use Research Center, Columbia University, NY Inserm U912, SE4S, Marseille Introduction
Routine HIV Monitoring Guideline of the HIV/AIDS Division at San Francisco General Hospital Statement of Guideline: Patients will be routinely evaluated and monitored for HIV parameters, antiretroviral
A 12-22 Month Follow-Up of HIV Patients Whose Therapy Was Optimized by Using HIV Genotyping Cynthia J. Carlyn, MD * Aldona L. Baltch, MD * Marty H. St. Clair, BS Mary J. George, PhD * Raymond P. Smith,
HIV/AIDS MAJOR ARTICLE Virological Control during the First 6 18 Months after Initiating Highly Active Antiretroviral Therapy as a Predictor for Outcome in HIV-Infected Patients: A Danish, Population-Based,
Combination Anti-Retroviral Therapy (CART) - Rationale and Recommendation M Dinaker INTRODUCTION The wide availability of effective, safe and mostly well tolerated combined anti-retroviral therapy (CART)
Antiretroviral Drugs in the Treatment and Prevention of HIV Infection Noga Shalev, MD Uses of Antiretroviral Agents Treatment of chronic HIV infection Prevention of mother-to-child transmission [PMTCT]
CONTACT: Lisa Rossi +1-412-641-8940 +1-412- 916-3315 (mobile) email@example.com The Basics of Drug Resistance: QUESTIONS AND ANSWERS HIV Drug Resistance and ARV-Based Prevention 1. What is drug resistance?
State of the Art Testing for HIV Drug Resistance Victor S.B. Jorden, MD, MPH Sindy M. Paul, MD, MPH Today, many patients with HIV infection are able to live longer and better lives, owing to the use of
AT&T Global Network Client for Windows Product Support Matrix January 29, 2015 Product Support Matrix Following is the Product Support Matrix for the AT&T Global Network Client. See the AT&T Global Network
143 Chapter 10 Human Immuno Deficiency Virus Infection Chapter 10 Human Immuno Deficiency Virus Infection...143 HIV infection...144 Clinical Features...146 Clinical Staging of HIV infection recommended
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
Poster # 42 Resistance in PBMCs Can Predict Virological Rebound after Therapy Switch in cart- Treated Patients with Undetectable HIV-RNA D Armenia 1, M Zaccarelli 2, V Borghi 3, W Gennari 3, A Giannetti
HIV Background, new developments, key strategies Drug Class Insight INTRODUCTION Human Immunodeficiency Virus (HIV) is the virus that can lead to Acquired Immunodeficiency Syndrome, or AIDS. No safe and
HBV screening and management in HIV-infected children and adolescents Linda Aurpibul M.D. Research Institute for Health Sciences, Chiang Mai University 8% HIV and Hepatitis B Co-infection Among Perinatally
Aktuell HIV-forskning 2014-05-06 Alexey Kashpersky Aktuell HIV-forskning Bot Smittsamhet Nya läkemedel HIV och åldrande Etc HPTN 052 Prevention Conclusion Early ART that suppresses viral replication led
DOI: 10.1111/j.1468-1293.2008.00561.x r 2008 Merck & Co., Inc. HIV Medicine (2008), 9, 285 293 ORIGINAL RESEARCH The prevalence of transmitted antiretroviral drug resistance in treatment-naïve patients
In Vitro Phenotypic Susceptibility of Human Immunodeficiency Virus Type 2 Clinical Isolates to Protease Inhibitors. Delphine Desbois, Bénédicte Roquebert, Gilles Peytavin, Florence Damond, Gilles Collin,
Population Pharmacokinetics of Atazanavir in Naïve HIV Infected Patients using Medication Events Monitoring System (MEMS) for drug intake timing ANRS -COPHAR clinical trial Céline Verstuyft Pharmacologie,
COMPARISON OF FIXED & VARIABLE RATES (25 YEARS) 2 Fixed Rates Variable Rates FIXED RATES OF THE PAST 25 YEARS AVERAGE RESIDENTIAL MORTGAGE LENDING RATE - 5 YEAR* (Per cent) Year Jan Feb Mar Apr May Jun
COMPARISON OF FIXED & VARIABLE RATES (25 YEARS) 2 Fixed Rates Variable Rates FIXED RATES OF THE PAST 25 YEARS AVERAGE RESIDENTIAL MORTGAGE LENDING RATE - 5 YEAR* (Per cent) Year Jan Feb Mar Apr May Jun
1 Read verbatim. 2 The Infectious Diseases Society of America (IDSA) Hepatitis C Knowledge Network offers monthly, 1 hour webinars to educate IDSA members on current recommended practices and treatments
TREATMENT FAILURE AND PATTERNS OF GENOTYPIC DRUG RESISTANCE MUTATIONS AMONG HAART EXPERIENCED HIV-1 PATIENTS AT KCMC Theonest Ndyetabura KILIMANJARO CHRISTIAN MEDICAL CENTRE / KILIMANJARO CLINICAL RESERCH
M42-Determinants M19 of HIV Sustained Viral Suppression in HIV/HCV-Coinfected Patients: role of the HCV sustained viral suppression F. Bani-Sadr 1-2, M-A Loko 2, E. Pambrun 2, M. Winnock 2, P. Carrieri
Protocol for the systematic review of virological outcomes after 12 Months of antiretroviral therapy in low and middle income countries 1. Authors James H. McMahon Alfred Hospital, Melbourne, Australia
HIV Guidelines. New Strategies. Santiago Moreno Hospital Universitario Ramón y Cajal Madrid HIV Guidelines. New Strategies. Outline HIV Guidelines What is new? New strategies Treatment as Prevention HIV
Antiretroviral Treatment Options for Patients on Directly Acting Antivirals for Hepatitis C PIs: atazanavir PIs: other Simeprevir with ritonavir- or cobicistat boosted PIs (significant simeprevir AUC).
15/05/2014 La sospensione dell ARV è sempre una cattiva idea? Adriano Lazzarin IRCCS Ospedale San Raffaele, Università Vita e Salute, Milano 6 Infectivology Today I due principi che guideranno il management
Paediatric HIV Drug Resistance in African Settings Dr Cissy Kityo Mutuluuza INTEREST Meeting May 5-9, 2014 Lusaka, Zambia Background: ART for children in sub- Saharan Africa 2.3 million children with HIV
Predicting the unpredictable: Transmission of drug-resistant HIV S.M. BLOWER 1, A.N. ASCHENBACH 1, H.B. GERSHENGORN 2 & J.O. KAHN 3 1 Department of Biomathematics and UCLA AIDS Institute, UCLA School of
Core Competencies: HIV/AIDS: HIV Basics HIV/AIDS JEOPARDY* ABOUT THIS ACTIVITY Time: 60 minutes Objectives: By the end of this session, participants will be able to: Reviewed their knowledge of HIV/AIDS
Perspective Incomplete Viral Suppression Under Potent Antiretroviral Therapy: Determinants of Treatment Outcome At the International AIDS Society USA course in Los Angeles in March 22, Steven G. Deeks,
SUPPLEMENT ARTICLE Initiating Therapy: When to Start, What to Use Martin S. Hirsch Massachusetts General Hospital, Harvard Medical School, Boston Decisions regarding whether to start combination antiretroviral
International AIDS Society - Industry Liaison Forum Meeting 5 March 2012 Treating HIV in children with tuberculosis Helen McIlleron, Division of Clinical Pharmacology University of Cape Town Challenges
Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States Visit the AIDSinfo website
Routine testing to reduce late HIV diagnosis in France. Cyrille Delpierre, Lise Cuzin, France Lert To cite this version: Cyrille Delpierre, Lise Cuzin, France Lert. Routine testing to reduce late HIV diagnosis
Issues in Perinatally HIV Infected Adolescents Gloria P Heresi, MD Professor of Pediatrics UTHealth, Houston Perinatally HIV Infected Adolescents Who are they? How many? Issues of special impact MTCT Race
HIV/Hepatitis C co-infection Update on treatment Eoin Feeney HIV/Hepatitis C coinfection Where we are now Current treatment regimens and outcomes What s coming soon Direct acting antivirals (DAAs) What
HIV and Hepatitis B CoInfection Douglas G. Fish, MD June 3, 2014 44 yo male with AIDS who had fallen out of care and returned in October 2013 Last seen in November 2012 CD4 at that time 340 cells/cmm HIV
Vol 1 October 2009 Clinical Pharmacist 393 Since the advent of combination antiretroviral therapy in the mid-1990s HIV-infected individuals are now living longer with improved quality of life. Medication
Highly active antiretroviral therapy and survival in HIV-infected Injection drug users: implications for the critical role of adherence Robert Hogg, PhD BC Centre for Excellence in HIV/AIDS and Simon Fraser
Chapter 36 Media Directory Drugs for Viral Infections Slide 23 Slide 27 Slide 29 Zidovudine Animation Saquinavir Mesylate Animation Acyclovir Animation Upper Saddle River, New Jersey 07458 All rights reserved.
Julius Bustamante, Pajaros Artwork from Hospital Audiences, Inc. (HAI), a nonprofit organization that inspires healing, growth and learning through access to the arts for the culturally underserved. Janssen
POSTEXPOSURE PROPHYLAXIS Bloodborne viruses Hepatitis B Hepatitis C HIV Hepatitis B Risk of seroconversion HBeAg negative 2% HBeAg positive 20-40% If seroconvert most recover completely and develop immunity
Clinical Commissioning Policy: Stribild for the treatment of HIV-1 infection in adults Reference: NHS England B06/P/x 1 Clinical Commissioning Policy: Stribild for the treatment of HIV-1 infection in adults
Liver Disease and Therapy of Hepatitis B Virus Infections University of Adelaide Catherine Scougall Arend Grosse Huey-Chi Low Allison Jilbert Fox Chase Cancer Center Chunxiao Xu Carol Aldrich Sam Litwin
Bloodborne Pathogens Exposure Policy and Procedures Employees of the State of South Dakota Department of Health Bloodborne Pathogens (HIV, HBV, and HCV) Exposure Management PEP Hotline 1-888-448-4911 DOH
A simple allele-specific polymerase chain reaction method to detect the Gly143Glu polymorphism in the human carboxylesterase 1 gene: importance of genotyping for pharmacogenetic treatment. Walter Soria
NON-OCCUPATIONAL POST EXPOSURE PROPHYLAXIS FOR SEXUAL ASSAULT SURVIVORS Carl LeBuhn, MD Post-Exposure Prophylaxis (PEP) The use of therapeutic agents to prevent infection following exposure to a pathogen
Journal of Theoretical Biology 246 (27) 499 59 www.elsevier.com/locate/yjtbi Optimal drug treatment regimens for HIV depend on adherence O. Krakovska, L.M. Wahl Department of Applied Mathematics, University
HIV Reports Antiretroviral Stewardship in a Pediatric HIV Clinic Development, Implementation and Improved Clinical Outcomes Alice J. Hsu, PharmD, BCPS, AQ-ID,* Asha Neptune, MA, MPH, Constants Adams, BS,
Chapter 3 South African guidelines and introduction to clinical cases 3.1. South African national antiretroviral guidelines When this book was published in 2012 the current national antiretroviral treatment
Acute Hepatitis C A short-term illness that usually occurs within the first six months after someone is exposed to the hepatitis C virus (HCV). 1 Antibodies Proteins produced as part of the body s immune
Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study Marguerite Guiguet, François Boué, Jacques Cadranel,
Didactic Series Updated Post-Exposure Prophylaxis (PEP) Guidelines Daniel Lee, MD UCSD Medical Center, Owen Clinic January 9, 2014 ACCREDITATION STATEMENT: University of California, San Diego School of
HIV/AIDS: Controversies 2008-10 1. Prevention 2. Treatment Josep M Gatell Hospital Clinic. Barcelona. firstname.lastname@example.org AIDS: year 2008-10 AIDS is a STD and a world wide epidemy (sub-saharan Africa,
London Therapeutic Tender Implementation: Guidance for Clinical Use 4 th June 2014 FINAL Contents 3. General principles 4. Financial impact of therapeutic tendering for branded ARVs 5. London ARV algorithm:
FEDERAL BUREAU OF PRISONS REPORT ON INFECTIOUS DISEASE MANAGEMENT What is the purpose of this report? The purpose of this report is to present the administrative policies and clinical guidelines for the
Section 1 HIV and AIDS Today What Are HIV and AIDS? Human immunodeficiency virus (HIV) is the virus that primarily affects cells of the immune system and that causes AIDS. Acquired immune deficiency syndrome
Key Components of HIV Medical Case Management: Treatment Adherence Prevention with Positives Updated 11/28/12 1 Treatment Adherence Counseling Every goal on the care plan must relate to HIV treatment/care.
CLINICAL SCIENCE in an Urban HIV Clinic Gregory K. Robbins, MD, MPH,* Brock Daniels, MPH,* Hui Zheng, PhD, Henry Chueh, MD, James B. Meigs, MD, MPH, and Kenneth A. Freedberg, MD, MSc* Background: Predictors
TUPE089 Virologic suppression outcomes of second-line antiretroviral therapy in a Nigerian cohort. Authors: Adedotun A. Adetunji 1, MBChB, MSc; Chad Achenbach 2, MD, MPH; Joseph Feinglass 3, PhD; Kristin
Second Silibinin Workshop, Cologne, 23 rd May 2014 Efficacy of lead-in silibinin and subsequent triple therapy in difficult-to-treat HIV/hepatitis C coinfected patients Dominique L Braun, MD Division of
Guidance for Industry Role of HIV Resistance Testing in Antiretroviral Drug Development U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research
Human Immunodeficiency Virus-1 Infection: Developing Antiretroviral Drugs for Treatment Guidance for Industry U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation
Southern African HIV Clinicians Society Clinical Guidelines Antiretroviral therapy in adults Introduction The magnitude of HIV infection in Southern African and the number of impoverished people who desperately
Non-linear mixed-effects models for tests of interaction or of lack of interaction in cross-over and parallel pharmacokinetic studies: application to the test of interaction between protease inhibitors
The value of urine protein/creatinine (upcr) and albumin/creatinine ratios (uacr) in assessing renal disease in HIV infection A Samarawickrama, S Holt, K Nambiar, M Fisher, Y Gilleece Brighton and Sussex
CONNECTICUT DEPARTMENT OF PUBLIC HEALTH HEALTH CARE AND SUPPORT SERVICES HIV MEDICATION ADHERENCE PROGRAM PROTOCOL Revised July 2013 HIV MEDICATION ADHERENCE PROGRAM PROGRAM OVERVIEW People living with
SURVEILLANCE OF INITIAL DRUG RESISTANT HIV-1 AMONG CHILDREN UNDER 18 MONTHS OF AGE NEWLY DIAGNOSED WITH HIV SURVEY REPORT AIDS & TB UNIT Ministry Of Health And Child Welfare Zimbabwe December 2012 1 Table
HIV and Hepatitis Co-infection Martin Fisher Brighton and Sussex University Hospitals, UK Useful References British HIV Association 2010 http://www.bhiva.org/documents/guidelines/hepbc/2010/ hiv_781.pdf
NON-OCCUPATIONAL POST EXPOSURE PROPHYLAXIS (npep) Guidance from the Michigan Department of Health and Human Services Division of Health, Wellness & Disease Control Revised June 2015 The Michigan Department
Should Expectations about the Rate of New Antiretroviral Drug Development Impact the Timing of HIV Treatment Initiation and Expectations about Treatment Benefits? Amin Khademi 1, R. Scott Braithwaite 2,3,